P-257: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in relapsed or refractory multiple myeloma: EXCALIBER-RRMM
Titel:
P-257: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in relapsed or refractory multiple myeloma: EXCALIBER-RRMM
Auteur:
Lonial, Sagar Berdeja, Jesus G. Dimopoulos, Meletios A. Jagannath, Sundar Knop, Stefan Quach, Hang RodrÃguez-Otero, Paula Richardson, Paul Acosta, Jorge Chu, Shuyu Chen, Min Abad, Patricia C. Morando, Juliane van de Donk, Niels W.C.J.